The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Dato-DXd generated durable responses and produced no new safety signals in patients with heavily pretreated, locally advanced/metastatic urothelial cancer.

Neeta Somaiah, MD, discusses ongoing research with novel agents that have emerged and those that could soon emerge in the sarcoma treatment paradigm.

Drs Geyer and Jabbour discuss ponatinib in Ph+ ALL, data with this agent plus blinatumomab, and how the safety profile of ponatinib affects its use.

Kevin T. Nead, MD, MPhil, details findings on the association between prevalent CVD and breast cancer and next steps for investigating the connection.

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.

Dr Jabbour discusses data that support the continued investigation of olverembatinib in patients with heavily pretreated chronic-phase CML.

KEAP1 and STK11 have emerged as potential biomarkers of response to immuno-oncology combinations in frontline NSCLC.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on treatment goals for anemia and transfusion independence in MDS.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the importance of treating anemia in myelodysplastic syndrome.

R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary.

Nazli Dizman, MD, explains the rationale for evaluating the impact of CBM588 on the gut microbiome in patients with metastatic RCC.

Guillermo Garcia-Manero, MD, discusses the rationale for investigating the dual inhibition of IRAK4 and FLT3 with emavusertib in MDS and AML

Naval G. Daver, MD, discusses the potential role for menin inhibitors in the frontline treatment of patients with acute myeloid leukemia.

A childhood dream became a reality for Montana native Kelly K. Hunt, MD, FACS, FSSO, who has changed the face of the surgical breast oncology workforce.

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

A humble mindset of the contributions he has made to genitourinary cancer care, Christopher J. Logothetis, MD, is also working to shape the next generation’s minds of medicine to improve outcomes further.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.

Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.

Bora Lim, MD, of The University of Texas MD Anderson Cancer, and Stephanie Graff, MD, of Brown University Health, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Elias Jabbour, MD, discusses frontline treatment considerations in newly diagnosed acute lymphocytic leukemia.

Isatuximab plus initial VRd and Rd maintenance demonstrated deep responses and MRD negativity in transplant-ineligible newly diagnosed multiple myeloma.

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

The therapeutic arsenal for patients with ALL in the first line and beyond is expanding beyond traditional approaches, enabling better outcomes for patients.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.